DelveInsight’s, “Vitiligo – Pipeline Insight, 2022,” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Vitiligo pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Vitiligo: Overview
Vitiligo is a complex pigment disorder that involves the skin, the hair, and occasionally the mucous membranes. It is a long-term condition where pale white patches develop on the skin. Vitiligo can affect any area of skin, but it commonly happens on the face, neck and hands. Vitiligo appears clinically as milk-white irregularly oval patches of skin, which are small at the beginning but enlarge gradually. The hair growing in the depigmented area is also white. Vitiligo can be triggered by stress to the melanin pigment-producing cells of the skin, the melanocytes. The triggers, which range from sunburn to mechanical trauma and chemical exposures, ultimately cause an autoimmune response that targets melanocytes, driving progressive skin depigmentation.
Pathogenesis
Vitiligo is a multifactorial disorder characterized by the loss of functional melanocytes. Multiple mechanisms have been proposed for melanocyte destruction in vitiligo. These include genetic, autoimmune responses, oxidative stress, generation of inflammatory mediators and melanocyte detachment mechanisms. Both innate and adaptive immunity of the immune system appear to be play role.
Diagnosis
The diagnosis of vitiligo is primarily made on clinical grounds and is based on history, clinical presentation, and family history (vitiligo, autoimmune disorders). The most extensively characterized clinical markers of active, progressive disease include: Koebner’s phenomenon, trichrome lesions, inflammatory lesions and confetti-like depigmentation.
Treatment
The optimal treatment of vitiligo will first depend on the subtype of the disease, percent of body surface area (BSA) involved, effect on quality of life, and the perception of the patient concerning the risk to benefit ratio. These treatments include phototherapy, topical and systemic immunosuppressants, and surgical techniques, stabilizing depigmented lesions and stimulating repigmentation. A successful treatment regimen to treat vitiligo incorporates three distinct approaches: reducing melanocytes stress, regulating the autoimmune response, and stimulating melanocyte regeneration.
"Vitiligo - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vitiligo pipeline landscape is provided which includes the disease overview and Vitiligo treatment guidelines. The assessment part of the report embraces, in depth Vitiligo commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vitiligo collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
This segment of the Vitiligo report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Vitiligo Emerging Drugs
Ruxolitinib: Incyte Corporation
Ruxolitinib is an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The therapy is currently under Phase III clinical development for the treatment of vitiligo.
AMG-714: Amgen
AMG-714, a fully human immunoglobulin monoclonal antibody (IgG1κ), binds to and inhibits the function of IL-15 in all of its forms (Cis, Trans, and soluble IL-15 bound to IL-15RA), and blocks IL-15-induced T cell proliferation. The molecule is currently in Phase II clinical evaluation for the treatment of vitiligo.
Further product details are provided in the report……..
This segment of the report provides insights about the different Vitiligo drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 22+ key companies which are developing the therapies for Vitiligo. The companies which have their Vitiligo drug candidates in the most advanced stage, i.e. Phase III include, Incyte Corporation.
DelveInsight’s report covers around 22+ products under different phases of clinical development like
Vitiligo pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Vitiligo therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vitiligo drugs.
Current Treatment Scenario and Emerging Therapies:
Introduction
Executive Summary
Vitiligo: Overview
Pipeline Therapeutics
Therapeutic Assessment
Vitiligo – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Vitiligo Collaboration Deals
Late Stage Products (Phase III)
Ruxolitinib: Incyte Corporation
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
AMG-714: Amgen
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
BOS 475: Boston Pharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Preclinical)
ARQ-252: Arcutis Biotherapeutics
Drug profiles in the detailed report…..
Inactive Products
Vitiligo Key Companies
Vitiligo Key Products
Vitiligo- Unmet Needs
Vitiligo- Market Drivers and Barriers
Vitiligo- Future Perspectives and Conclusion
Vitiligo Analyst Views
Vitiligo Key Companies
Appendix
List of Table
Table 1: Total Products for Vitiligo
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Vitiligo
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Incyte Corporation
• Amgen
• Boston Pharmaceuticals
• Arcutis Biotherapeutics
• Pfizer
• Dermavant Sciences
• Clinuvel Pharmaceuticals
• Celgene
• TWi Biotechnology
• AXIM Biotechnologies
• Arrien Pharmaceuticals
